Evidence map›Paper›PMID 41315365›Full record

ArticleNature communications2025

The CTLH ubiquitin ligase substrates ZMYND19 and MKLN1 negatively regulate mTORC1 at the lysosomal membrane.

Yin Wang, Yifei Liao, Yizhe Sun, Bidisha Mitra, Rui Guo, Brenda Iturbide Piedras, Shaowen White, Hsin-Yao Tang, John M Asara, Italo Tempera and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The many faces of the GID/CTLH E3 ligase complex.Biochemical Society transactions · 2025
    Review
  2. RANBP9 and RANBP10 cooperate in regulating non-small cell lung cancer proliferation.Journal of experimental & clinical cancer research : CR · 2025
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Yin WangDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8137-7496
Yifei LiaoDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Yizhe SunDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5986-3826
Bidisha MitraDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Rui GuoDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4584-1324
Brenda Iturbide PiedrasDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Shaowen WhiteDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Hsin-Yao TangThe Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1838-018X
John M AsaraDivision of Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7450-2589
Italo TemperaThe Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7893-2914
Paul M LiebermanThe Wistar Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3935-9921
Benjamin E GewurzDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. bgewurz@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-3965-3418

Funding

Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Italo Tempera · 2023 to 2026
$12.0M
Regulation of the Epstein-Barr Virus Lytic SwitchR01AI164709 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2021 to 2026
$3.1M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Epstein-Barr Virus Driven Tonsillar Versus Peripheral B-cell One-Carbon Metabolic Network RemodelingR01DE033907 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2024 to 2026
$1.5M
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cellsR00DE031016 · NIDCR · TUFTS UNIVERSITY BOSTON · PI GUO, RUI · 2023 to 2025
$747k
American Cancer Society (American Cancer Society, Inc.) PF-23-1144614-01-IBCDAmerican Cancer Society (American Cancer Society, Inc.) PF-24-1194768-01-TBEAmerican Cancer Society (American Cancer Society, Inc.) PF-24-1250090-01-IBCDAmerican Cancer Society (American Cancer Society, Inc.) PF-24-1308318-01-TBEDivision of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI164709NCI NIH HHS P01 CA120964NCI NIH HHS P01 CA269043NCI NIH HHS R50 CA221838NIAID NIH HHS R01 AI164709NIDCR NIH HHS R00 DE031016NIDCR NIH HHS R01 DE033907U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) P01CA269043
6 · The paper itself

Abstract

Most Epstein-Barr virus-associated gastric carcinoma (EBVaGC) harbor non-silent mutations that activate phosphoinositide 3 kinase (PI3K) to drive downstream metabolic signaling. To gain insights into PI3K/mTOR pathway dysregulation in this context, we perform a human genome-wide CRISPR/Cas9 screen for hits that synergistically blocked EBVaGC proliferation together with the PI3K antagonist alpelisib. Multiple subunits of carboxy terminal to LisH (CTLH) E3 ligase, including the catalytic MAEA subunit, are among top screen hits. CTLH negatively regulates gluconeogenesis in yeast, but not in higher organisms. The CTLH substrates MKLN1 and ZMYND19, which highly accumulated upon MAEA knockout, associate with one another and with lysosome outer membranes to inhibit mTORC1. Rather than perturbing mTORC1 lysosomal recruitment, ZMYND19 and MKLN1 block the interaction between mTORC1 and Rheb and also with mTORC1 substrates S6 and 4E-BP1. Thus, CTLH enables cells to rapidly tune mTORC1 activity at the lysosomal membrane via the ubiquitin/proteasome pathway.

Indexed as

Intracellular MembranesLysosomesMechanistic Target of Rapamycin Complex 1Ubiquitin-Protein LigasesCell Line, TumorCell ProliferationCRISPR-Cas SystemsHEK293 CellsHumansPhosphatidylinositol 3-KinasesSignal TransductionMechanistic Target of Rapamycin Complex 1Phosphatidylinositol 3-KinasesUbiquitin-Protein Ligases

Identifiers

PMID41315365
PMCPMC12663577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.